Chicago Atlantic BDC, Inc. filed a Current Report on Form 8-K on November 12, 2026, announcing its financial results for the third quarter ended September 30, 2026, and disclosing details of a pending merger with Chicago Atlantic Real Estate Finance, Inc.
Inflection Point Acquisition Corp. VII filed a Form 8-K on November 12, 2026, reporting that on November 11, 2026, it entered into the Second Amendment to the Business Combination Agreement with Merger Sub and Elroy Air, Inc., modifying stock exchange procedures and lock-up agreement …
Axalta Coating Systems Ltd. filed a Form 425 on November 11, 2026, disclosing that the UK Competition and Markets Authority has completed a Phase 1 review of the proposed merger with Akzo Nobel N.V. and identified competition concerns in the supply of vehicle refinish …
Addex is a Geneva-based, clinical-stage biopharmaceutical company developing small molecule allosteric modulators for neurological disorders. Its lead candidate, dipraglurant, is being evaluated for future development in brain injury recovery, and it has GABAB programs aimed at substance use disorders and chronic cough.
Alvotech is a biotechnology company that develops and manufactures biosimilar medicines, with an integrated operation in Reykjavik, Iceland. It has five approvedBiosimilarsmarketed across multiple global markets, sold largely through commercial partners.
Aveanna is an Atlanta-based home care provider operating in 39 states, serving medically complex, high-cost patients with services such as nursing, hospice, rehabilitation, school-based nursing and enteral nutrition delivery. Its largest segment, private duty services, generated $574.2 million of third quarter revenue.
Beyond Air is a Garden City, New York-based commercial-stage medical device and biopharmaceutical company developing nitric oxide therapies. Its only commercial product, LungFit PH, is a cylinder-free system approved by the FDA for term and near-term neonates with hypoxic respiratory failure.
Fennec is a specialty pharmaceutical company based in Research Triangle Park, North Carolina. The company describes PEDMARK as the first and only FDA-approved therapy to reduce the risk of cisplatin-related hearing loss in pediatric patients with localized, non-metastatic solid tumors. A European version is …
PepGen is a Boston-based, clinical-stage biotechnology company founded in 2018. Its Enhanced Delivery Oligonucleotide technology uses cell-penetrating peptides to improve the uptake of conjugated oligonucleotide therapies. Its lead candidate, PGN-EDODM1, is being studied in myotonic dystrophy type 1 in the Phase 2 FREEDOM2-DM1 trial.
SeaStar is a Denver-based, commercial-stage medical device company developing extracorporeal therapies built on its Selective Cytopheretic Device platform, which aims to neutralize overactive immune cells in critically ill patients. Its first commercial product received FDA approval in 2024 for pediatric use.